Pharmaceutical On the regulatory front last week, there was a major setback for Sarepta Therapeutics on Monday, after the US Food and Drug Administration issued a complete response letter (CRL) for its Duchenne muscular dystrophy candidate Vyondys 53 (golodirsen). On a positive note, there was FDA approval for the TB Alliance’s pretomanid treatment-resistant tuberculosis (TB). Research news included that the NEPTUNE trial of AstraZeneca’s Imfinzi and tremelimumab had once again failed in lung cancer. 25 August 2019